GenoType MTBC VER 1.X
Molecular assay for identification and differentiation of the M. tuberculosis complex
Identification and differentiation of the M. tuberculosis complex
Tuberculosis (TB) is caused by the members of the Mycobacterium tuberculosis complex. The M. tuberculosis complex includes the species M. tuberculosis, M. africanum, M. bovis, M. microti and M. canettii. Above all, early identification of the pathogen is necessary for the selection of appropriate therapy and of crucial importance for a successful treatment.
The BCG vaccine strain is a derivative of M. bovis attenuated in its pathogenicity and is used for immunization against TB and for immunotherapy of malignant tumours, such as bladder cancer. Detection of the BCG strain usually does not require any medication, and therefore requires an exact differentiation from the other members of the M. tuberculosis complex.
M. bovis causes TB in domestic and wild animals, but is also a significant human pathogen. Its distinction from M. tuberculosis is particularly important for epidemiological reasons as well as because of its intrinsic resistance to the first-line antibiotic pyrazinamide (PZA). Additional species of the M. tuberculosis complex have different disease progression and transmission patterns and may require adjusted treatment regimens.
GenoType MTBC VER 1.X offers a rapid solution for the differentiation of the M. tuberculosis complex within 5 hours from solid and liquid culture. The assay allows the reliable detection and differentiation of M. tuberculosis/M. canettii, M. africanum, M. microti, M. bovis subsp. bovis (also known as M. bovis), M. bovis subsp. caprae (also known as M. caprae), and M. bovis BCG. This molecular genetic assay is part of the comprehensive portfolio of Bruker’s DNA•STRIP assays, used by mycobacteria laboratories worldwide.
Fast and reliable differentiation of the M. tuberculosis complex
Rapid and reliable differentiation of the M. tuberculosis complex is enabled by highly specific and sensitive molecular test. A Universal Control displays the presence of mycobacteria and gram-positive bacteria with high G+C content. The MTBC control shows that members of the MTB complex are present.
Furthermore, M. tuberculosis/M. canettii, M. africanum, M. microti, M. bovis subsp. bovis, M. bovis subsp. caprae, and M. bovis BCG are differentiated by a specific banding pattern on the DNA•STRIP.
For illustrative purposes only. For result interpretation, please refer to Instructions for Use.
Enabled by DNA•STRIP technology
The well-proven DNA•STRIP technology is based on PCR and reverse hybridization. It enables highly efficient diagnostics for all throughputs with low implementation costs. All DNA•STRIP products can be combined with each other. This permits joint execution of several human-genetic and microbiological parameters.
Low-cost implementation in mycobacteria routine
GenoType MTBC assay can be carried out with minimal investment, which means low-cost implementation for every laboratory size. DNA extraction can be performed manually with GenoLyse® VER 1.0. The subsequent PCR reaction takes place in a standard thermal cycler. The most convenient way is to use the GTQ-Cycler 96 as the respective PCR program for the assay, as well as other DNA•STRIP assays, is already pre-installed. For the subsequent detection, hybridization steps can be performed partially automated with the TwinCubator or fully automated with the GT-Blot 48.
Please contact your local representative for availability in your country.
Not for sale in the USA.
Legal Manufacturer is Hain Lifescience GmbH – A Bruker Company
